Double-barreled approach doubles survival times in recurrent glioma patients

January 31, 2017 Christoph Graener

Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly-appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mike Ward, Informa Pharma Intelligence insight global director of content, how his company’s approach has potential to double brain cancer survival.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Martin Duvall – CEO, Tocagen

Previous Article
PhaseRx makes more noise than silence with mRNA delivery

PhaseRx president and CEO Dr. Robert Overell explains how delivering messenger RNA inside diseased cells ma...

Next Article
Second Genome CEO predicts paradigm shift with microbiome discovery

California biotech, which has backing from major pharmas, explains the application of its microbiome discov...